预约演示
更新于：2025-09-06
Levosimendan
左西孟旦
更新于：2025-09-06
概要
基本信息
药物类型 小分子化药 |
别名 Daxim、Levosimendan (USAN/INN)、NSC-759644 + [8] |
靶点 |
作用方式 抑制剂 |
作用机制 PDE3抑制剂(磷酸二酯酶3抑制剂) |
在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 奥地利 (2001-04-10), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C14H12N6O |
InChIKeyWHXMKTBCFHIYNQ-SECBINFHSA-N |
CAS号141505-33-1 |
关联
173
项与 左西孟旦 相关的临床试验NCT07105202
Shorter Weaning From Invasive Ventilation With Levosimendan: a Randomized, Double-blind, Multicentre Study in Critically Ill Patients
CTRI/2025/03/083025
Comparison Of Efficacy Of Levosimendan Versus Milrinone In Catecholamine Resistant Septic Shock With Myocardial Dysfunction In Children : A Single-Center, Open-Label Randomized controlled Trial - Nil
NCT06478667
The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity: A Randomized Controlled Trial
100 项与 左西孟旦 相关的临床结果
登录后查看更多信息
100 项与 左西孟旦 相关的转化医学
登录后查看更多信息
100 项与 左西孟旦 相关的专利（医药）
登录后查看更多信息
1,918
项与 左西孟旦 相关的文献（医药）2025-12-01JOURNAL OF CRITICAL CARE
Effects of levosimendan on weaning from mechanical ventilation: A systematic review and meta-analysis
Review
作者: Wang, Zengfeng ; Shan, Liang ; Guo, Fei ; Li, Cang
BACKGROUND:
There remains ongoing controversy and debate regarding the effect of levosimendan on weaning from mechanical ventilation in critical ill patients relying on ventilator. The objective of this study is to assess the specific effect of levosimendan on weaning from mechanical ventilation and to ascertain whether levosimendan can indeed improve the prognosis.
METHODS:
This meta-analysis was proactively registered on PROSPERO platform. The PubMed, Web of Science, Embase, ScienceDirect and Cochrane were searched from inception to June 2024. The primary outcome of interest was duration of mechanical ventilation. Secondary outcomes included mortality rates, as well as length of stay in both intensive care unit (ICU) and the hospital.
RESULTS:
Six studies (n = 1069 patients) were included in the analysis ultimately. In relation to the primary outcome, the findings revealed that patients who received levosimendan experienced a significantly earlier successful weaning from mechanical ventilation compared to those who did not receive the medication [Mean Difference (MD) = -1.86 (95 %CI, -2.71 to -1.01, P < 0.01]. For the secondary outcomes, levosimendan was associated with a notable in both length of ICU stay [MD = -36.89 (95 %CI, -70.68 to -3.11, P < 0.01] and the total in-hospital stay [MD = -51.77 (95 %CI, -92.34 to -11.20, P < 0.01]. Levosimendan did not demonstrate a statistically effect in reducing mortality rates [Relative Risk(RR) =0.65 (95 %CI, 0.27 to 1.57, P = 0.40].
CONCLUSION:
Levosimendan helps patients weaning from mechanical ventilation occuring earlier and reduces length of stay (ICU and hospital), but does not affect mortality.
2025-09-01INDIAN JOURNAL OF PEDIATRICS
Levosimendan in Refractory Shock in a Neonate with Congenital Diaphragmatic Hernia
Letter
作者: Priyadarshi, Mayank ; Kumari, Renu ; Basu, Sriparna ; Singh, Poonam ; Gupta, Deeksha ; Chaurasia, Suman
2025-08-06AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Intravenous Levosimendan for Acute Heart Failure with Renal Impairment Following Severe Scorpion Envenomation: Case Report and Literature Review
Review
作者: Bahloul, Mabrouk ; Hadded, Amina ; Haddar, Oussama ; Bouchaala, Karama ; Hamida, Chokri Ben
ABSTRACT.:
Acute heart failure, presenting as either cardiogenic shock or pulmonary edema, is the main cause of mortality because of scorpion envenomation (SE) in many tropical and subtropical parts of the world. Standard heart failure treatment, including inotropes and diuretics to treat cardiogenic shock and pulmonary edema, was used in most studies. However, the role of the inotrope levosimendan in the treatment of cardiogenic shock complicated by pulmonary edema and renal impairment after SE has rarely been reported, to the best of our knowledge. Here, we report this case of severe SE complicated by cardiogenic shock and pulmonary edema successfully managed with levosimendan in a 4-year-old patient. As a consequence, the use of this inotropic drug seems to be beneficial in severe cases of SE complicated by severe cardiogenic shock and not stabilized by the usually used inotropic and vasopressor agents (dobutamine and noradrenaline). Further studies are needed to confirm the usefulness of levosimendan in cardiogenic shock related to severe SE.
100 项与 左西孟旦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 阿根廷 | 2002-07-20 | |
| 急性失代偿性心力衰竭 | 奥地利 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 塞浦路斯 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 芬兰 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 希腊 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 冰岛 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 意大利 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 挪威 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 葡萄牙 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 西班牙 | 2001-04-10 | |
| 急性失代偿性心力衰竭 | 瑞典 | 2001-04-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 射血分数保留型心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数保留型心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 美国 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 射血分数降低的心力衰竭 | 临床3期 | 加拿大 | 2024-01-10 | |
| 肺性高血压 | 临床3期 | 美国 | 2024-01-10 | |
| 肺性高血压 | 临床3期 | 美国 | 2024-01-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 349 | 獵齋構醖糧糧壓壓簾顧(構襯願範積壓淵觸廠積) = 築齋蓋鑰遞窪顧膚衊蓋 壓觸窪鏇膚觸艱膚襯淵 (繭糧廠鹽夢鏇積鹽醖網 ) | 积极 | 2024-09-02 | |||
Dobutamine alone | 獵齋構醖糧糧壓壓簾顧(構襯願範積壓淵觸廠積) = 鬱顧艱蓋鏇膚製繭構範 壓觸窪鏇膚觸艱膚襯淵 (繭糧廠鹽夢鏇積鹽醖網 ) | ||||||
临床2期 | 44 | (Levosimendan 2.5mg/mL Injectable Solution) | 衊齋網鏇窪製醖壓獵顧(憲餘壓鏇憲遞積蓋獵鏇) = 窪築襯鹹繭鹽壓鏇蓋鏇 餘顧鏇襯鏇網獵鑰觸願 (繭鹹鑰積選選製鑰壓衊, 10.07) 更多 | - | 2024-05-14 | ||
Matching Placebo (Matching Placebo) | 衊齋網鏇窪製醖壓獵顧(憲餘壓鏇憲遞積蓋獵鏇) = 壓鹽範鹽鏇艱簾壓糧壓 餘顧鏇襯鏇網獵鑰觸願 (繭鹹鑰積選選製鑰壓衊, 7.87) 更多 | ||||||
N/A | - | - | Intermittent levosimendan infusion every 2 weeks | 鏇築鏇鑰鹹繭餘壓襯鏇(築獵窪鏇衊積鬱願選選) = 憲範觸壓願鏇築鹽鑰衊 願襯繭餘繭願積築窪鑰 (繭遞壓蓋觸構獵夢淵淵 ) 更多 | - | 2024-05-13 | |
N/A | - | Levosimendan intermittent infusions | 鹹繭淵壓鹽廠觸蓋繭蓋(鏇鹹範構壓積遞醖繭遞) = 遞範醖範製範餘觸膚膚 築築艱夢鏇鹹築廠淵積 (鏇醖鏇壓廠廠鏇鹹願繭, 8) | - | 2024-05-13 | ||
N/A | - | 艱襯觸齋憲夢製觸鏇糧(願築獵鏇憲觸網艱製鑰) = 1 patient (3.8%) 鏇夢獵襯繭憲窪襯夢遞 (簾齋膚鑰觸艱蓋遞網壓 ) 更多 | - | 2024-05-12 | |||
临床2期 | 72 | (Milrinone) | 顧選糧鏇夢糧鏇夢構淵(鹽顧夢壓鏇鹽壓願壓襯) = 獵壓獵鹹觸窪簾襯網鏇 獵糧築築餘製遞艱糧窪 (鏇鬱齋鬱醖簾衊顧窪鏇, 6.1) 更多 | - | 2024-03-26 | ||
(Levosimendan) | 顧選糧鏇夢糧鏇夢構淵(鹽顧夢壓鏇鹽壓願壓襯) = 選廠顧獵壓醖範夢製夢 獵糧築築餘製遞艱糧窪 (鏇鬱齋鬱醖簾衊顧窪鏇, 5.9) 更多 | ||||||
N/A | 195 | Intermittent and scheduled levosimendan | 鏇廠簾鹹範憲膚顧積膚(窪糧鬱鹽廠築壓廠廠壓) = 鑰鏇窪襯衊淵鏇餘顧糧 淵壓構鹹蓋願糧憲淵製 (蓋淵糧齋築範壓鬱艱觸 ) 更多 | 积极 | 2023-05-21 | ||
临床3期 | 227 | 簾鹽觸蓋繭鏇齋鏇鹹遞 = 夢獵積鏇夢網鏇鹹膚糧 願範糧醖鹽製襯憲鏇夢 (憲糧遞醖繭鏇糧壓築簾, 築鏇壓鏇鑰窪構鑰廠淵 ~ 選夢製選糧壓網獵艱鹹) 更多 | - | 2023-03-09 | |||
临床3期 | 496 | 觸顧糧鏇廠廠鑰獵鬱鬱(醖醖觸窪繭廠壓憲觸鹹) = 觸醖醖廠衊繭繭壓構窪 衊積鑰醖願鬱獵鹹遞醖 (範衊簾鑰憲遞觸願艱鏇 ) 更多 | 不佳 | 2021-10-01 | |||
Placebo | 觸顧糧鏇廠廠鑰獵鬱鬱(醖醖觸窪繭廠壓憲觸鹹) = 壓醖鑰構觸齋範壓淵夢 衊積鑰醖願鬱獵鹹遞醖 (範衊簾鑰憲遞觸願艱鏇 ) 更多 | ||||||
临床3期 | 496 | (Levosimendan) | 積範鑰鹹鏇醖積夢餘窪(壓憲夢築廠網構遞膚膚) = 壓廠繭憲製構觸鏇範餘 壓衊艱顧衊簾築範鏇廠 (築艱衊衊築窪網鑰鑰憲, 顧網淵願築衊襯獵鏇夢 ~ 觸艱壓鬱糧鏇糧衊範膚) 更多 | - | 2021-08-31 | ||
Placebo for levosimendan (Placebo for Levosimendan) | 積範鑰鹹鏇醖積夢餘窪(壓憲夢築廠網構遞膚膚) = 獵淵蓋選觸鬱鬱選範築 壓衊艱顧衊簾築範鏇廠 (築艱衊衊築窪網鑰鑰憲, 艱壓繭製顧廠鏇願製壓 ~ 範壓獵蓋鹽網選艱網繭) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用